Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
Glenmark to reduce R&D; spending as challenges mount
Glenmark Pharmaceuticals to limit R&D spending to 11-12% of sales for three years as it confronts a challenging business environment in key markets, particularly the US Scrutinizer's Report
Sub: Proceedings and Voting Results of the 39th Annual General Meeting (AGM) of Glenmark Pharmaceuticals Limited ('the Company') held on September 29, 2017 Please find enclosed the following: 1.Summary of the proceedings of the AGM of the Company as required under Regulation 30, Para A of Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('Listing Regulations') - Annexure A.... Outcome of AGM
Sub: Proceedings and Voting Results of the 39th Annual General Meeting (AGM) of Glenmark Pharmaceuticals Limited ('the Company') held on September 29, 2017 Please find enclosed the following: 1.Summary of the proceedings of the AGM of the Company as required under Regulation 30, Para A of Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('Listing Regulations') - Annexure A.... Recent approvals to help Glenmark Pharma scale up FY18 growth
Glenmark Pharmaceuticals has gained over five per cent since its lows this month on brokerage upgrades which highlight the upside from product launches in the US and potential of out-licensing deals. Prior to the upgrades, the stock was under pressure given expectations of drug price erosion of 10-15 per cent in FY18 and falling contribution from generic version of Zetia, a drug used in bringing down cholesterol levels. The six month sales under exclusivity for this drug came to an end in the June quarter and generated about $175 million in revenues for Glenmark. In fact, one of the reasons for the company's overall revenues growing at 20 per cent year-on-year and operating profit rising 42 per cent in FY17 was due to Zetia sales.Barring Zetia and India business, performance in the June quarter was nothing to write home about. What had compounded matters was the currency depreciation in Latin American market and discontinuing sales in Venezuela resulting in a 31 per cent decline in... Press Release / Media Release
Dear Sir, Glenmark Pharmaceuticals receives ANDA approval for Desonide Lotion,0.05% With reference to the above subject, find attached media release which is self explanatory. Request you to kindly take the same on record. Glenmark expects generics to drive growth over next 3-4 years
Glenmark Pharmaceuticals has said its pipeline of speciality and innovative products over the next three to four years is expected to act as a defence against generics price erosion and competition,... Glenmark charts out new path for growth
The company will pursue oncology, dermatology and respiratory as three chosen therapy areas of focus and will straddle the entire value chain of products. Glenmark gets USFDA nod for chest pain tablets
Glenmark Pharmaceuticals' US arm has received final approval from USFDA for its Nitroglycerin sublingual tablets used for preventing chest pain due to coronary artery disease. Glenmark... Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record.